Response to Letters Regarding Article, "Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study"

Circulation - United States
doi 10.1161/circulationaha.111.072090
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Phosphodiesterase-5 Inhibition in Heart Failure With Preserved Ejection Fraction: Trading Therapy for Prevention

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2017English

Pulmonary Hypertension Is Related to Peripheral Endothelial Dysfunction in Heart Failure With Preserved Ejection Fraction

Circulation. Heart failure
MedicineCardiovascular MedicineCardiology
2014English

Diffuse Right Ventricular Fibrosis in Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension

ESC heart failure
Cardiovascular MedicineCardiology
2020English

Pulmonary Hypertension in Heart Failure Preserved Ejection Fraction: Prevalence, Pathophysiology, and Clinical Perspectives

Circulation. Heart failure
MedicineCardiovascular MedicineCardiology
2014English

Heart Rate in Heart Failure With Preserved Ejection Fraction: Target or Marker?

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2017English

A 70-Year-Old Woman With Heart Failure With Preserved Ejection Fraction

CMAJ
Medicine
2014English

Prognosis in Heart Failure With Preserved Ejection Fraction

sudan heart journal
2017English

Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction: Acute Hemodynamic Effects of Inhaled Iloprost

Pulmonary Circulation
PulmonaryRespiratory Medicine
2015English

Treating Heart Failure With Preserved Ejection Fraction: Learning From Pulmonary Fibrosis

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy